本帖最后由 老马 于 2012-1-13 21:20 编辑
) d& \) M) Q6 R o# G" ^, M- a: Y
( J$ U: I3 w% m3 v0 o3 E爱必妥和阿瓦斯丁的比较- ^. E. t( L! T
% ~, ?* b+ T8 g* L3 O
http://cancergrace.org/lung/2008/08/30/bms099-os-neg// w x% X& H; c1 U
' z3 E( {4 @7 v! ~
8 }. k, }9 Z& }' ^+ @http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 v# s) \: t8 J! T: ?( _- g7 B
==================================================
1 S% Q& H% n7 J: ?! gOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)3 r s. d* d" W* A" X- K: N
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" t9 X# |' F# u. u( HResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
0 ]2 _% y) v0 k- L/ q
|
显身卡
